No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
CN Stock MarketDetailed Quotes
600789 Shandong Lukang Pharmaceutical
- 9.07
- -0.37-3.92%
Noon Break May 17 11:29 CST
8.13BMarket Cap30.33P/E (TTM)
9.42High8.66Low1.62MlotVolume9.24Open9.44Pre Close1.46BTurnover18.05%Turnover Ratio32.98P/E (Static)896.06MShares10.6752wk High2.21P/B8.13BFloat Cap5.0452wk Low10.38Limit Up896.06MShs Float19.53Historical High8.50Limit Down8.05%Amplitude0.65Historical Low0.06Dividend TTM9.04Avg Price856.32KlotAsk0.61%Div YieldTTM100Lot Size719.22KlotBid
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Synthetic organisms are now differentiated! Big bulls have advanced to the 5th straight board, and policy expectations haven't been met yet?
There will be major policies in the future
The top-level file will be released soon! The concept of synthetic biology has risen to prominence, and the pace of industrial development has accelerated
Trillion racetrack
Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) Looks Inexpensive But Perhaps Not Attractive Enough
With a price-to-earnings (or "P/E") ratio of 21.7x Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) may be sending bullish signals at the moment, given that almost half of all companies in China
Lukang Pharmaceutical (600789.SH): Net profit of 67.3076 million yuan in the first quarter, up 47.32% year on year
Gelonghui, April 23 | Lu Hang Pharmaceutical (600789.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 1,799 billion yuan, up 7.72% year on year; net profit attributable to shareholders of listed companies was 67.3076 million yuan, up 47.32% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 53.3717 million yuan, up 28.99% year on year; basic earnings per share were 0.08 yuan.
Shandong Lukang PharmaceuticalLtd's (SHSE:600789) Earnings Are Weaker Than They Seem
Last week's profit announcement from Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) was underwhelming for investors, despite headline numbers being robust. We did some digging and found some w
Is The Market Rewarding Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
Shandong Lukang PharmaceuticalLtd (SHSE:600789) has had a rough three months with its share price down 15%. It seems that the market might have completely ignored the positive aspects of the company
Comments
The company's low ROE and stagnant net income growth over the past five years are worrisome. Despite high profit retention, the low return rate may be hindering earnings growth. The market seems to overlook the company's positive fundamentals, focusing more on the negatives.
Is The Market Rewarding Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) With A Negative Sentiment As A Result Of Its Mixed Fundamentals? 1
The company's low P/E ratio is due to declining medium-term earnings. Investors see no significant potential for earnings improvement to justify a higher P/E ratio. Without profitability improvement, the P/E ratio could fall even lower.
Read more
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
%Chg